vs
FS Bancorp, Inc.（FSBW）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
FS Bancorp, Inc.的季度营收约是REGENXBIO Inc.的1.3倍（$40.0M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs 12.0%），FS Bancorp, Inc.自由现金流更多（$51.9M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 6.2%）
FS Bancorp, Inc.是总部位于美国的银行控股公司，为华盛顿第一安全银行的母公司，主要面向美国太平洋西北地区客户提供各类个人及商业银行服务，包括存款产品、住房贷款、小微企业融资、建筑贷款等，核心业务涵盖零售银行、商业银行及住房信贷三大板块。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FSBW vs RGNX — 直观对比
营收规模更大
FSBW
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出31.0%
12.0%
自由现金流更多
FSBW
多$104.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $40.0M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 25.8% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 12.0% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $1.11 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSBWRGNX
| Q4 25 | $40.0M | $30.3M | ||
| Q3 25 | $39.3M | $29.7M | ||
| Q2 25 | $37.3M | $21.4M | ||
| Q1 25 | $36.1M | $89.0M | ||
| Q4 24 | $35.7M | $21.2M | ||
| Q3 24 | $37.2M | $24.2M | ||
| Q2 24 | $36.3M | $22.3M | ||
| Q1 24 | $35.5M | $15.6M |
净利润FSBWRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $9.2M | $-61.9M | ||
| Q2 25 | $7.7M | $-70.9M | ||
| Q1 25 | $8.0M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $10.3M | $-59.6M | ||
| Q2 24 | $9.0M | $-53.0M | ||
| Q1 24 | $8.4M | $-63.3M |
毛利率FSBWRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FSBWRGNX
| Q4 25 | 25.8% | -190.0% | ||
| Q3 25 | 29.5% | -176.3% | ||
| Q2 25 | 26.2% | -296.3% | ||
| Q1 25 | 26.2% | 13.6% | ||
| Q4 24 | 27.6% | -242.1% | ||
| Q3 24 | 26.5% | -256.6% | ||
| Q2 24 | 31.3% | -251.3% | ||
| Q1 24 | 29.7% | -408.8% |
净利率FSBWRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 23.4% | -208.3% | ||
| Q2 25 | 20.7% | -331.8% | ||
| Q1 25 | 22.2% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 27.6% | -246.3% | ||
| Q2 24 | 24.7% | -237.7% | ||
| Q1 24 | 23.7% | -405.4% |
每股收益（稀释后）FSBWRGNX
| Q4 25 | $1.11 | $-1.30 | ||
| Q3 25 | $1.18 | $-1.20 | ||
| Q2 25 | $0.99 | $-1.38 | ||
| Q1 25 | $1.01 | $0.12 | ||
| Q4 24 | $0.88 | $-0.99 | ||
| Q3 24 | $1.29 | $-1.17 | ||
| Q2 24 | $1.13 | $-1.05 | ||
| Q1 24 | $1.06 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $307.7M | $102.7M |
| 总资产 | $3.2B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FSBWRGNX
| Q4 25 | $28.2M | $230.1M | ||
| Q3 25 | $61.3M | $274.2M | ||
| Q2 25 | $33.2M | $323.3M | ||
| Q1 25 | $62.7M | $267.9M | ||
| Q4 24 | $31.6M | $234.7M | ||
| Q3 24 | $40.3M | $255.5M | ||
| Q2 24 | $33.0M | $290.4M | ||
| Q1 24 | $45.4M | $338.7M |
股东权益FSBWRGNX
| Q4 25 | $307.7M | $102.7M | ||
| Q3 25 | $300.5M | $161.5M | ||
| Q2 25 | $297.2M | $213.7M | ||
| Q1 25 | $298.8M | $274.2M | ||
| Q4 24 | $295.8M | $259.7M | ||
| Q3 24 | $288.9M | $301.4M | ||
| Q2 24 | $284.0M | $348.3M | ||
| Q1 24 | $277.9M | $390.7M |
总资产FSBWRGNX
| Q4 25 | $3.2B | $453.0M | ||
| Q3 25 | $3.2B | $525.2M | ||
| Q2 25 | $3.2B | $581.0M | ||
| Q1 25 | $3.1B | $490.9M | ||
| Q4 24 | $3.0B | $466.0M | ||
| Q3 24 | $3.0B | $519.1M | ||
| Q2 24 | $2.9B | $569.4M | ||
| Q1 24 | $3.0B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $72.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $51.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | 129.8% | -174.0% |
| 资本支出强度资本支出/营收 | 50.9% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $107.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FSBWRGNX
| Q4 25 | $72.3M | $-52.3M | ||
| Q3 25 | $44.6M | $-56.0M | ||
| Q2 25 | $7.1M | $-49.3M | ||
| Q1 25 | $8.2M | $33.6M | ||
| Q4 24 | $50.8M | $-31.6M | ||
| Q3 24 | $-891.0K | $-40.5M | ||
| Q2 24 | $9.9M | $-45.5M | ||
| Q1 24 | $275.0K | $-55.5M |
自由现金流FSBWRGNX
| Q4 25 | $51.9M | $-52.8M | ||
| Q3 25 | $41.6M | $-56.5M | ||
| Q2 25 | $5.9M | $-49.7M | ||
| Q1 25 | $7.8M | $32.6M | ||
| Q4 24 | $49.2M | $-32.7M | ||
| Q3 24 | $-1.5M | $-40.9M | ||
| Q2 24 | $9.6M | $-46.0M | ||
| Q1 24 | $-82.0K | $-56.0M |
自由现金流率FSBWRGNX
| Q4 25 | 129.8% | -174.0% | ||
| Q3 25 | 105.9% | -189.9% | ||
| Q2 25 | 15.7% | -232.8% | ||
| Q1 25 | 21.7% | 36.6% | ||
| Q4 24 | 137.7% | -154.2% | ||
| Q3 24 | -4.1% | -168.9% | ||
| Q2 24 | 26.6% | -206.2% | ||
| Q1 24 | -0.2% | -358.5% |
资本支出强度FSBWRGNX
| Q4 25 | 50.9% | 1.7% | ||
| Q3 25 | 7.7% | 1.7% | ||
| Q2 25 | 3.5% | 1.8% | ||
| Q1 25 | 1.0% | 1.2% | ||
| Q4 24 | 4.6% | 5.1% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 0.8% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率FSBWRGNX
| Q4 25 | — | — | ||
| Q3 25 | 4.86× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 1.02× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.03× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSBW
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
